Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Clinical trial NCT07570966 · WITHDRAWN

Trial details

NCT number: NCT07570966
Sponsor: Novartis Pharmaceuticals
Status: WITHDRAWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced HR+/HER2- Breast Cancer Advanced CCNE1-amplified Solid Tumors Metastatic Castration-resistant Prostate Cancer (mCRPC)

Start date: 2026-06-30
Primary completion: 2031-08-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.